Design, Synthesis and Evaluation of Small Molecules as ALK5 Inhibitors
Second Edition
Versandkostenfrei!
Versandfertig in 1-2 Wochen
29,99 €
inkl. MwSt.
PAYBACK Punkte
15 °P sammeln!
A new series of imidazo[2,1-b][1,3,4]thiadiazoles were synthesized as transforming growth factor-ß (TGF- ß) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitors. These compounds were evaluated for their ALK5 inhibitory activity in an enzyme assay and their TGF-ß -induced Smad2/3 phosphorylation inhibitory activity in a cell-based assay. One of the compound from this series displayed prominent ALK5 inhibition (IC50 = 0.0012 µM) and elective inhibition (91%) against the P38¿ kinase at 10 µM. The binding mode of this compound by XP docking studies showed that it...
A new series of imidazo[2,1-b][1,3,4]thiadiazoles were synthesized as transforming growth factor-ß (TGF- ß) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitors. These compounds were evaluated for their ALK5 inhibitory activity in an enzyme assay and their TGF-ß -induced Smad2/3 phosphorylation inhibitory activity in a cell-based assay. One of the compound from this series displayed prominent ALK5 inhibition (IC50 = 0.0012 µM) and elective inhibition (91%) against the P38¿ kinase at 10 µM. The binding mode of this compound by XP docking studies showed that it ¿ts well into the active site cavity of ALK5 by forming broad and tight interactions. Lipinski's rule and in silico ADME pharmacokinetic parameters are within the acceptable range defined for human use, thereby indicating their potential as a drug-like molecules.
Andere Kunden interessierten sich für
